RxDoctor Payments Data

Meredith Neale

Family · Murfreesboro, TNNPI 1669137246

Payments from drug & device makers

$479in general payments, 2019–2025

Across 25 payments — averaging $19.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Paratek Pharmaceuticals, Inc.$66
  • Novo Nordisk$61
  • AbbVie$55
  • GSK$54
  • Lilly USA, LLC$52
  • Pfizer$46
  • plus $144 from 8 others

What the payments were for

  • Food & beverage$479100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Paratek Pharmaceuticals, Inc.3$66
Novo Nordisk3$61
AbbVie3$55
GSK3$54
Lilly USA, LLC3$52
Pfizer2$46
Amgen1$25
Solventum Corporation1$23
Sanofi Pasteur Inc.1$20
Dexcom, Inc.1$18
VBI Vaccine (delaware) Inc.1$16
Qiagen, LLC1$15
Cashflow Solutions, LLC1$13
Reprise Biomedical, Inc.1$13

How this compares

$479 in reported general payments places this provider in the 50th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$3,529
Medicare patients
16
Services billed
65

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Breo ElliptaFluticasone/Vilanterol14$10,513
Duloxetine Hcl26$1,302
Atorvastatin Calcium122$991
Gabapentin23$383
Metformin Hcl53$353
Albuterol Sulfate HfaAlbuterol Sulfate24$346
Rosuvastatin Calcium30$332
Lisinopril57$319
Levothyroxine Sodium51$295
Losartan Potassium39$277
Montelukast Sodium19$245
Metoprolol Succinate18$217
Pantoprazole Sodium25$175
Omeprazole26$163
Carvedilol12$151

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKBreo Ellipta$54$10,51314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 6,706 family providers in Tennessee.

Other family in Murfreesboro

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →